Latest Pharmaceutical Research and Manufacturers of America Stories
The announcement was made today by Pharmacist Partners, The Clinical Knowledge Organization(TM) (CKO). As a CKO, Pharmacist Partners utilizes pharmacists to provide education and advocacy to healthcare practitioners on behalf of its pharmaceutical clients. NEW YORK, May 14, 2013 /PRNewswire-iReach/ -- Mr. Castellani, one of the most respected visionaries in Corporate America, has been appointed to Pharmacist Partners' Advisory Board. Currently, Mr. Castellani leads PhRMA, an...
CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics(TM)--a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins--announced today that Henri A. Termeer, Genzyme's retired chairman, president, and CEO, has joined Moderna's board of directors. Over nearly 30 years at Genzyme, Termeer built one of the world's most innovative and commercially successful biotechnology...
Genentech Ranks Highest in Physician Satisfaction with Biopharmaceutical Manufacturers WESTLAKE VILLAGE, Calif., April 25, 2013 /PRNewswire/ -- Although the role of pharmaceutical sales representatives has changed in recent years, physicians continue to perceive the sales representative as the leading influence on their relationship with biopharmaceutical companies, according to the J.D. Power and Associates 2013 Physician Manufacturer Experience Study--Oncology(SM )released today....
John Castellani, president and CEO, of Pharmaceutical Research and Manufacturers of America will be the keynote speaker. Cole Werble, senior editor of The RPM Report, a highly regarded industry publication, will ensure a day of provocative discussion on relevant issues. NEWARK, N.J., April 23, 2013 /PRNewswire-USNewswire/ -- The Food and Drug Administration is still waiting for pharmaceutical companies to begin submitting the first new medicines in a class of prescription drugs...
SAN DIEGO, April 22, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that Michael Narachi, president and chief executive officer, has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a term of two years. PhRMA represents the country's leading innovative biopharmaceutical research and...
SAN DIEGO, April 12, 2013 /PRNewswire-USNewswire/ -- Robert J. Hugin, chairman and CEO of Celgene Corporation, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association's annual meeting. Also elected were Ian C. Read, president and CEO of Pfizer Inc, as chairman-elect of the PhRMA Board of Directors, and Kenneth C. Frazier, Chairman, President and CEO of Merck & Co, Inc., as Board treasurer. (Logo:...
PhRMA Member Companies Invested $48.5 Billion in R&D in 2012 WASHINGTON, April 11, 2013 /PRNewswire-USNewswire/ -- Investment in research and development (R&D) by member companies of the Pharmaceutical Research and Manufacturers of America (PhRMA) remained strong at an estimated $48.5 billion in 2012, despite economic, scientific, and business challenges. These efforts are highlighted in PhRMA's 2013 Biopharmaceutical Research Industry Profile released today....
Research Supported by Biopharmaceutical Companies is Boost to Texas Economy WASHINGTON, March 25, 2013 /PRNewswire/ -- Working in collaboration with university medical schools and science centers, local hospitals and clinical research facilities, America's biopharmaceutical companies have conducted more than 8,200 clinical trials of new medicines in Texas over the last 13 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The...
New research highlights significant economic benefit of clinical trials in the Lone Star State and opportunities for Texas patients to contribute to medical progress AUSTIN, Texas, March 20, 2013 /PRNewswire/ -- WHO: Sen. Bob Deuell (R) - Greenville; Rep. Jim Murphy (R) - Houston; Tom Kowalski, President, Texas Healthcare and Bioscience Institute; Dr. Curtis Triplitt,...
More Than 900 Biologic Medicines and Vaccines in Development WASHINGTON, March 11, 2013 /PRNewswire-USNewswire/ -- America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). (Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO) The report includes biologics in human clinical trials...
